REIN THERAPEUTICS INC (RNTX) Stock Analyst Earnings Estimates
NASDAQ:RNTX - Nasdaq - US00887A2042 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | |||||||||||
| EBITDA YoY % growth | -15.44M | -12.56M 18.65% | -17.94M -42.83% | -22.88M -27.54% | -31.68M -38.46% | -29.8M 5.93% | -20.34M 31.74% | -26.49M -30.24% | -27.48M -3.74% | -15.229M 44.58% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.03M | -12.89M 19.59% | -18.17M -40.96% | -23.01M -26.64% | -31.9M -38.64% | -29.96M 6.08% | -20.5M 31.58% | -26.61M -29.80% | -27.65M -3.91% | -15.348M 44.49% | N/A -144.65% | N/A 37.25% | N/A -35.23% | N/A -16.87% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -41.20 15.10% | -25.80 37.38% | -12.60 51.16% | -5.80 53.97% | -6.02 -3.79% | N/A 65.91% | -3.78 -84.19% | N/A 75.17% | N/A 41.30% | N/A |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.22 50.13% | -0.26 5.56% | -0.20 90.73% |
| Revenue Q2Q % growth | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.61M 37.94% | -6.63M -9.21% | -5.61M 48.48% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.25 70.93% | -0.25 | 0.00 | -0.04% |
| Q4 2024 Q2Q % growth | -2.20 -42.86% | -0.14 | -2.06 | -1,451.70% |
| Q3 2024 Q2Q % growth | -0.27 55.88% | -0.42 | 0.15 | 35.44% |
| Q2 2024 Q2Q % growth | -0.45 15.16% | -0.43 | -0.02 | -5.04% |
| Q1 2024 Q2Q % growth | -0.86 18.10% | -0.14 | -0.72 | -493.76% |
| Q4 2023 Q2Q % growth | -1.54 -50.98% | -0.17 | -1.37 | -820.61% |
| Q3 2023 Q2Q % growth | 56.29% | -0.61 | % | |
| Q2 2023 Q2Q % growth | 70.53% | -0.53 | % | |
| Q1 2023 Q2Q % growth | -1.05 41.67% | -0.88 | -0.17 | -19.70% |
| Q4 2022 Q2Q % growth | -1.02 36.25% | -1.37 | 0.35 | 25.37% |
| Q3 2022 Q2Q % growth | -1.40 | -1.68 | 0.28 | 16.82% |
| Q2 2022 Q2Q % growth | -1.80 -50.00% | -1.84 | 0.04 | 1.96% |
| Q1 2022 Q2Q % growth | -1.80 -12.50% | -1.56 | -0.24 | -15.08% |
| Q4 2021 Q2Q % growth | -1.60 33.33% | -1.63 | 0.03 | 1.96% |
| Q3 2021 Q2Q % growth | -1.40 46.15% | -1.43 | 0.03 | 1.96% |
| Q2 2021 Q2Q % growth | -1.20 57.14% | -1.50 | 0.30 | 19.78% |
| Q1 2021 Q2Q % growth | -1.60 66.67% | -1.09 | -0.51 | -47.07% |
| Q4 2020 Q2Q % growth | -2.40 53.85% | -2.60 | 0.20 | 7.73% |
| Q3 2020 Q2Q % growth | -2.60 53.57% | -3.02 | 0.42 | 13.88% |
| Q2 2020 Q2Q % growth | -2.80 46.15% | -3.83 | 1.03 | 26.80% |
| Q1 2020 Q2Q % growth | -4.80 51.02% | -4.13 | -0.67 | -16.19% |
| Q4 2019 Q2Q % growth | -5.20 | -5.56 | 0.36 | 6.46% |
| Q3 2019 Q2Q % growth | -5.60 | -4.85 | -0.75 | -15.58% |
| Q2 2019 Q2Q % growth | -5.20 | -4.59 | -0.61 | -13.29% |
| Q1 2019 Q2Q % growth | -9.80 | -6.78 | -3.02 | -44.48% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |